Investors, Strategics & Innovators

Atul Butte, MD, PhD is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and inaugural Director of the Bakar Computational Health Sciences Institute (bchsi.ucsf.edu) at the University of California, San Francisco (UCSF). Dr. Butte is also the Chief Data Scientist for the entire University of California Health System, the tenth largest by revenue in the United States, with 20 health professional schools, 6 medical schools, 6 academic health centers, 10 hospitals, and over 1000 care delivery sites. Dr. Butte has been continually funded by NIH for 20 years, is an inventor on 24 patents, and has authored nearly 300 publications, with research repeatedly featured in the New York Times, Wall Street Journal, and Wired Magazine. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the Obama Administration as a White House Champion of Change in Open Science for promoting science through publicly available data. Dr. Butte is also a co-founder of three investor-backed data-driven companies: Personalis (IPO, 2019), providing medical genome sequencing services, Carmenta (acquired by Progenity, 2015), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston, then received his PhD from Harvard Medical School and MIT.

29 years of extensive global experience as a MedDevice and MedTech Executive and Investor. Adept at Investment, General Management, Mergers & Acquisitions, Finance and Corporate Strategy. Passionate about transforming businesses through growth and innovation, developing talent, optimizing resources, creating enterprise value for shareholders, developing new products and executing strategic initiatives to deliver top line growth and increase profitability.

Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997.

“Life Sciences investing is not just about recognizing good science,” Papiernik says, “it’s about people — learning how to interact with co-investors, limited partners, and entrepreneurs. Listening, discerning, negotiating, and finding common interests.”

When you find the right people to invest in, he adds, “you can bank on them more often than you can predict how the science is going to turn out.” He looks for entrepreneurs with the nimbleness to adapt, “even if that means a making a major shift from where one starts out on the journey.”

Antoine actively invests for our Capital Funds. He has been an initial investor and active board member in a number of public companies, including Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), Movetis (sold to Shire), and Pixium Vision. Trade sale success stories include CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis), Ethical Oncology Science (EOS, sold to Clovis Oncology) and Recor Medical (sold to Otsuka).

He has also invested in and is a board member of private companies Reflexion Medical, Tissium, Pi-Cardia, SafeHeal, Noema Therapeutics, Ablacare, Highlife and Inspirna (formerly Rgenix).

Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. He has been selected twice for the Forbes Midas List, an annual ranking recognizing the world’s top venture capital investors. Antoine is one of the few European and life science investors to have appeared on the prestigious list.

Coming soon...

As a member of the Managing Board of a global innovation leader in healthcare, I have the honor, responsibility, and pleasure to drive better access to high-quality care for more people around the world. Thanks to our unique capabilities in patient twinning, precision therapy, digital data, and AI, we’re strategically positioned to help healthcare systems achieve better patient outcomes.

Fred Moll is a visionary in the healthcare industry and has been called “the father of robotic surgery” – his inventions have helped pave the way for improved surgical procedures for decades. Fred is currently the Chief Development Officer of Johnson and Johnson Medical Devices Companies. A serial entrepreneur, Fred co-founded Intuitive Surgical, Inc. (NASDAQ:ISRG), Hansen Medical (NASDAQ:HNSN), Restoration Robotics (NASDAQ:HAIR), and most recently was the founder and CEO of Auris Health (acquired by J&J April ’19 for $5.75B).

His innovation career began during medical training when he invented the safety trocar, which helped create the field of modern laparoscopic surgery.

Fred is a distinguished speaker and lecturer, a prolific inventor and is the author of numerous scientific articles. He currently serves on the boards of several healthcare companies, including Procept BioRobotics, ShockWave Medical, GI Windows, and RefleXion.

Executive leader with strong experience and success in early stage as well as Fortune 500 health companies. Most recent operating role was President and CEO of Nuelle, Inc., a women's consumer health company (acquired). Currently Managing Director at KCK Medical Technologies Investment Group. Director/Board Chair/Exec Chair of Aerin Medical, Sonex Health, Revelle Aesthetics, Candesant Biomedical and Barologics within KCK portfolio. Independent Board Director outside of KCK in consumer health. Interests: Women's health, Consume

He is widely sought after for his strategic insight and knowledge of structuring M&A transactions and currently serves on the boards of several healthcare companies, including Shockwave Medical (NASDAQ: SWAV), Avail Medsystems, RefleXion Medical, Tissium and Neptune Medical.

Bio coming soon.

Coming soon...

Bio coming soon.

Coming soon...

Bio coming soon.

Coming soon...

Bio coming soon.

Bio coming soon.

Scott will join his team of exclusive sponsors to host the Emerging Medtech Summit. Scott's mission at the meeting will be to connect the investors, innovators and strategics that are driving the future of medtech.

Scott is the President, CEO and Founder of Life Science Intelligence.  He has been in the medtech market intelligence business for over 20 years supporting venture funded startups, major strategics, and life science investors as they navigate the ever-changing medtech marketplace.  Prior to founding LSI, he held senior executive roles with renowned life science data providers including Medical Data International, Medtech Insight and Windhover Information.  He has held leadership roles as a strategic partner for Elsevier Business Intelligence, Health Research Intelligence, and Informa Business Intelligence.  Scott and his team at LSI have conducted numerous market research projects for top medical device manufacturers including Johnson & Johnson, Medtronic, Boston Scientific, Abbott, Becton Dickinson, Teleflex, Cardinal Health, GE Healthcare, and Stryker, among others. 

Bio coming soon.

Daniel Hawkins is the founder and CEO of Avail Medsystems, a medical technology company creating a network where medical expertise sharing can occur between healthcare professionals and experts to and from the operating room anytime, anywhere.

Over the past 25 years in the medical technology field, Daniel’s mission has been to identify and close gaps that prevent patients from getting the best possible healthcare. He is an inventor on over 140 patents and applications, and has held roles in both large and emerging companies, including Advanced Cardiovascular Systems, Inc., Endologix, Restore Medical, EnteroMedics, and Intuitive Surgical. Daniel is a co-founder of Calibra Medical, acquired by Johnson & Johnson, and founder of Shockwave Medical, Inc. (NASDAQ: SWAV). 

Daniel has an MBA from Stanford University and a BS in Economics from The Wharton School of the University of Pennsylvania. In 2017, Daniel was honored by Goldman Sachs as one of its Top 100 Most Intriguing Entrepreneurs.

Health technology executive with extensive experience developing disruptive technology and creating new markets. Passionate about early stage ventures, entrepreneurship, and intrapreneurial efforts that require market analysis, needs assessment, product and business model discovery and definition, corporate strategic planning, and go-to-market execution.

As a leader and builder of innovative healthcare companies like Cognito Therapeutics, Cognoa, and WellnessFx as well as being a part of the healthcare venture investment team at Morningside, I have worked with teams to build therapeutic and device companies that develop novel medicines or Digital Therapeutics (DTx) to address unmet medical needs. I am most interested in companies who I feel can leverage novel approaches to address unmet medical needs and underserved patient populations.

Serial life science entrepreneur and innovator dedicated to globally commercializing world changing medical technologies. Leadership experience from early idea stages through global product launches in both private and public companies, with significant domestic and international management experience.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Lu Zhang, Founder and Managing Partner of Fusion Fund, is a renowned Silicon Valley investor, a serial entrepreneur, and a Stanford Engineering alumna. Lu is a World Economic Forum - Young Global Leader. She has also garnered other accolades including the Featured Honoree in VC of Forbes 30 Under 30, Silicon Valley Women of Influence, Town & Country 50 Modern Swans – Entrepreneurship Influencer, and was recently selected as the Best 25 Female early-stage Investor by Business Insider (2021). Prior to starting Fusion Fund, she was the Founder and CEO of a medical device company (acquired in 2013). Lu is a frequent speaker at tech events and conferences such as Davos World Economic Forum, Future Investment Initiative (FII), Forbes, Web Summit, SuperReturn, etc., and serves as a mentor and advisor to several tech innovation programs in Silicon Valley. Lu is the board member of the Youth Council of Future Forum and Future Science Award. Lu is also on the Jury Board of Cartier’s Young Leader Award. She received her M.S. in Materials Science and Engineering from Stanford University.

Former litigation attorney - have been involved in Healthcare since 1999. Focused on debt and equity strategy for BioPharma, Device, Dx/Tools and Digital Health. Have written numerous thought pieces detailing the flow of capital into venture healthcare (investment and fundraising) as well as M&A and IPO activity.

I am a Managing Director in the Healthcare Practice at SVB, where I run Business Development on the West Coast, and mange Venture Capital relationships. I help investors understand and analyze historical and current market trends around investments and returns, and assist CEOs and C-level management with equity and debt strategy, business plans, exit comps and access to capital.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Huennekens has more than 25 years of experience in the medical device industry, specializing in clinical advancement through innovative R&D and technology-based initiatives. He currently serves as Executive Chairman of the Board for Acutus Medical (IPO in 2020).  He has held a number of executive leadership roles within the healthcare industry, accelerating the next generation of digital surgery for Verb Surgical and leading Volcano Corporation, an image guided therapy device company, to its IPO in 2006. He holds an MBA from Harvard University and a BS in Business Administration from the University of Southern California. Huennekens currently sits on the boards of public companies Viewray and NuVasive.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Coming Soon...

Bio coming soon.

Chris Eso currently has dual responsibility as Vice President of Business Development & Strategy for both the Structural Heart & Aortic operating unit and the Cardiovascular Portfolio, which includes eight cardiovascular operating units across Medtronic. Chris joined Medtronic in 2011 and has held numerous business development, M&A and strategy positions of increasing responsibility and scope over his tenure at Medtronic in both the businesses and corporate functions.

Previous Roles:

Chris brings more than 25 years of successful professional business and general management experience within the pharmaceutical, biotech and medical device industries, in addition to Medtronic, including Allergan, Watson Pharmaceuticals, Agilent Technologies, and Peregrine Pharmaceuticals. Most of his experience is in a business/corporate development and strategy capacity where he has led more than 50 transactions with consideration of approximately $15 billion, as well as general management capacity running a $50 million revenue-generating wholly-owned subsidiary of a publicly-traded company

College Background:

Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.

Bio coming soon.

Business Development, Venture Capital Investment, Mergers & Acquisitions, Sales Management, and Marketing in Medical Device

Specialties: Venture Capital Investment, Mergers and Acquisitions, Market analysis and business plan development for emerging technologies; upstream market strategy, sales management and team leadership; sales team training and development.

Bio coming soon.

Bio coming soon.

As Executive Vice President, Strategic Partnerships, Lisa leverages her global product commercialization experience to help forge long-term collaborations with a core focus on Veranex’s strategic partners and their portfolio management.

Lisa has 25+ years of healthcare product commercialization with companies in the U.S., Europe, and China, with a special emphasis on MedTech innovation. As an active member of the MedTech and investor communities, Lisa is an advisor to many startups and accelerators including CLSI’s FAST program, MedTech Innovator, and UCSF Health Hub. She also serves as an advisor to the Cleveland Clinic MedTech Advisory Board, the Mayo Clinic’s Executive Steering Committee for the Surgical Innovation Summit, UCLA Biodesign, UCLA’s Technology Ventures Group Advisory Board, and RedCrow Angel Investor platform. Lisa serves on the Board of Directors for MarinHealth system, a partner of UCSF and is Co-Chair of MedtechWomen’s Annual MedTech Vision Conference in 2021-22. Lisa has a keen interest in the latest MedTech innovation trends and authors Veranex’s MedTech Pioneers blog, which spotlights MedTech leadership and their groundbreaking work.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Global executive with more than 15 years of experience in the healthcare industry, leading mid-to-large size multinationals in the areas of business development, strategy and M&A. Experienced at leveraging inorganic growth to build sustainable businesses while further developing the organizational capabilities and the innovation pipeline of the organization. Team player used to leading in international multi-decision level environments through a focus on addressing change management, collaboration, and efficient decision-making.

Kevin Chu is a Principal on the healthcare team at F-Prime Capital. Prior to F-Prime Capital, Kevin was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on development and commercial strategy across multiple therapeutic areas.

Kevin is currently based in the San Francisco office, and works across the healthcare sub-sectors including Therapeutics, MedTech, and Healthcare IT and Services, and also works closely with Eight Roads Ventures China healthcare team to manage F-Prime’s existing and new investment efforts in China.

Josh is a Special Partner on NEA's healthcare team and has worked closely with NEA since his time as an EIR back in 1995, stepping up as a General Partner to lead our medtech/healthtech practice from 2015 to 2021. In addition to his continuing role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 9 companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003, Nuelle, acquired by AyTu Biosciences in 2014, and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo (NASDAQ: EAR), Allay Therapeutics, Lungpacer, Revelle Aesthetics, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT, and is a Fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.

Mr. Bikoff is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health. While at Cardinal Health, he worked to deploy over $6 billion of capital through M&A and minority investments. Most recently, Mr. Bikoff was the Director of North America Marketing for the Cordis cardiovascular franchise. Mr. Bikoff currently serves on the board of Polares Medical and is a board observer at Ceribell, Endogenex, Limflow, and Nalu. He previously served as a board observer at Amphora (acquired), Eargo (EAR), and RxSight (RXST), and was also actively involved in Longitude Capital’s investment in Axonics Modulation Technologies (AXNX) and PROCEPT BioRobotics (PRCT). Mr. Bikoff began his career in Deloitte Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University.

David Greenwald, Ph.D., is a Vice President, Business Development on the Therapeutics team and joined the Firm in 2018. In this role, Dr. Greenwald is responsible for searching for new investment opportunities, supporting business development of Deerfield private portfolio companies, and providing his expertise to Deerfield’s research collaborations and venture creation efforts. Prior to joining Deerfield, Dr. Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures. He was a co-founder and Chief Executive Officer of Relay Technology Management, Inc. and a co-inventor of the Relay Innovation Engine software platform. After Relay was acquired by Decision Resources Group, Dr. Greenwald served as the Director of Client Solutions at Decision Resources Group. Before that, he was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked on developing diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his Ph.D. in Genetics from Tufts University. Dr. Greenwald currently serves on the Boards of Jaguar Gene Therapy, Axovia Therapeutics, and Apertura Gene Therapy.

Fouad Azzam is a Partner in the EQT Life Sciences team. Fouad worked for LSP from 2007 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. 

Prior to joining LSP, Fouad worked as a Managing Director Eastman Ventures and Director at Eastman Chemical Company in Kingsport TN, USA. Prior to Eastman Chemical Company, Fouad was part of the Research & Business Development group at Occidental Chemical Company in Grand Island NY, USA.

Fouad holds an Ph.D. in Chemical Engineering from the University of Akron, USA and an M.B.A. from SUNY Buffalo, USA.

Bio coming soon.

Prior to joining HealthpointCapital, Milen Todorov was a Director in the global healthcare team at UBS Investment Bank, focusing on the musculoskeletal sector. While at UBS, Milen executed over 25 M&A and capital raising transactions with aggregate value in excess of $35 billion. He began his career in economic litigation consulting at Charles River Associates. Mr. Todorov received a B.A. in Economics from Middlebury College and an MBA from the Tuck School of Business at Dartmouth.

Bio coming soon.

Dr. Azin Parhizgar served as Chief Executive Officer, President and Board Member at Claret Medical. She is an experienced and successful medical device industry executive and entrepreneur. Prior to Claret Medical, she served as the Chief Operating Officer of Conor Medsystems which led to the acquisition of the company by Johnson & Johnson, Inc. in 2007. She spent one year post-merger with Johnson & Johnson for full integration of the companies. Between 1996-2000 she held the position of Executive Vice President for Arterial Vascular Engineering, which was acquired by Medtronic. She spent two years at Medtronic post-merger in increasing roles of responsibility leading to her role as Executive Vice President of Emerging Ventures and New Technologies. Dr. Parhizgar has served as an advisor to emerging medical device technology companies including several Board of Directors and Scientific Advisory Board positions. Dr. Parhizgar received both her Ph.D. in Cell, Gene and Tissue Engineering and her M.Sc. in Biomechanical Engineering and Artificial Organ Design from Brown University.

Bio coming soon.

Bio coming soon.

Frederik is a Co-Founder and General Partner of 415 CAPITAL. He has been an investor in more than a dozen of innovative medical technology companies and led 415’s investments in Supira Medical, CorFlow Therapeutics, Cardiac Success, Aktiia, Distalmotion and R3 Vascular. He currently serves as a Board Director at Cardiac Success and R3 Vascular. Prior to co-founding 415 CAPITAL, Frederik served as Business Development Manager at Regis Medical, a Germany based medical device distributor where he helped source and evaluate new partnerships and investment opportunities. Previously, Frederik worked in HSBC’s Leveraged & Acquisition Finance group in New York City where he structured financings for private equity-backed buyouts and corporate M&A transactions including several large-cap Healthcare transactions. Before moving to New York City, he was an Analyst at HSBC in London where he advised clients on cross-border M&A transactions and IPOs. Frederik holds an Hon. B.A. in Economics magna cum laude from the University of Toronto (University College), Canada.

Frank has almost 40 years of investing, management, sales & marketing experience in the MedTech space, the last 30 years as serial investor and entrepreneur. As an investor, he has funded over 40 MedTech companies. As an entrepreneur, he has founded, built, and exited several successful European MedTech distribution companies, including Regis Medical GmbH, Ovum Ventures GmbH (sold to Medtronic in 2009) and Cardiologic GmbH (sold to Boston Scientific in 2002). His companies have commercialized over 20 novel medical device technologies in Europe and helped establish new clinical standards of care, including cerebral embolic protection, transcatheter aortic valve replacement (TAVR), ultrasound renal denervation, and the world’s first pre-mounted coronary stents (Arterial Vascular Engineering). Following Boston Scientific’s acquisition of Cardiologic GmbH, Frank served as the General Manager of Boston Scientific’s Interventional Cardiology Division Germany. Previously, he held several management positions at St. Jude Medical (now part of Abbott), Inc., W. L. Gore & Associates, and AHSC American Hospital Supply Corp. (now part of Baxter).

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund.

Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea).

Prior to this recent role, Sascha successfully advised multiple renowned clients in corporate finance and strategy projects working as (senior) consultant for PricewaterhouseCoopers and the Boston Consulting Group. He was selected for the global leadership development program in his previous role and was named a global high-potential in PwC.

Sascha studied technology management in Munich, Singapore and Boston and  holds a Master from Munich University of Technology with majors in entrepreneurial finance and chemistry, magna cum laude. In his master thesis he analyzed the specific challenges of biotech VC financing rounds. Later he completed his PhD studies in banking and finance while already working for PwC. He is a regular speaker on corporate finance topics for German universities and business schools.

During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.

Bio coming soon.

Matt is an entrepreneurial business leader with 15 years of experience in building and managing dynamic technology companies.

He has a proven track record of successfully bringing innovative products and services to market.

Prior to Genesis Innovation Group, he was COO of Conpoto, and VP of Finance, COO and President of LeanLogistics.

Ramin Mousavi is a dynamic executive with an outstanding history of building high-performing teams and achieving exceptional results in the medical device and high-tech industries — from developing to launching and commercializing breakthrough and transformational products. He is currently the President & Chief Executive Officer (CEO) of CathWorks, an innovative global medical device company focused on transforming the diagnosis and treatment of coronary artery diseases. CathWorks is dedicated to improving the care of patients suffering from coronary artery disease by providing clinicians the most comprehensive and objective data through CathWorks digital health platform, a combination of advanced algorithms, artificial intelligence, machine learning and cutting-edge user interface. A rising star of the medical device industry, Ramin has executive leadership and operational experience in general management, marketing, strategy, product development, and commercialization across multiple market segments. Prior to CathWorks, Ramin led the patient monitoring and digital health portfolio at Baxter International. Previously, he held various leadership assignments at Edwards Lifesciences, Panasonic, and Rockwell Collins.

https://www.linkedin.com/in/raminmousavi

https://www.twitter.com/RaminMousaviMBA

Bio coming soon.

Bio coming soon.

Tyler J. Stowater is Partner and Vice President of Bluestem. He graduated from South Dakota State University with a BS Degree in Agriculture Economics (1984) and a MS Degree in Economics (1986). Tyler spent eleven years with the State of South Dakota's Bureau of Finance and Management. During his tenure, Tyler held the position of budget analyst, state economist, and deputy commissioner. In 1997, Tyler left the State to become an Assistant Vice President at Citibank South Dakota with business analysis responsibilities in the North American Cards Customer Service Unit. Tyler joined Bluestem in 2000 and is currently in charge of portfolio management with responsibilities including the evaluation of prospective companies, structuring, negotiating, and performing due diligence for various investments made by Bluestem. He monitors and provides assistance to existing portfolio companies and holds multiple Board of Director positions. In the spring of 2016, Tyler was given the Distinguished Alumnus award at the 62nd Annual Celebration of Excellence in Economics at South Dakota State University. Tyler is married to Joni (Klosterman) and they have two children, McKenzie (Otterberg) and McCord.

Bio coming soon.

Bio coming soon.

Dr. Marengère is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.

Dr. Marengère joined TVM in 2012 and has 23 years of venture capital experience. He was a key driver of the implementation of the TVM LSI I investment strategy which resulted in a number of investments. He is a Director on the Boards of Emovi Inc.; Acanthas Pharma; Occelaris Pharma; Ixchelsis; PRCL Pharma; Panthera Dental; FAAH Pharma; Kaneq Biosciences; Acer Therapeutics as well as Rapid Micro Biosciences. Luc was on the Board of Colucid Pharma Inc. and Aurka Pharma which were recently sold to Eli Lilly for US $960M and US $575M respectively.

Dr. Marengère brings a significant track record to TVM given his long standing experience as  a Venture Capitalist. Very notable deals during Luc‘s previous tenure as Managing Partner at VG Partners include Cytochroma Inc. (sold to Opko for US$ 400M); VisualSonics (sold to Sonosite for US $75M) and CITA Neuropharma (sold to Vernalis Plc for US$ 85M). Prior to joining VG Partners, Luc focused on making venture investments in the life science sector while at La Caisse De Depot‘s venture capital group SOFINOV as well as MDS Capital and MedTech Partners.

Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. Luc holds a Ph.D. from University of Toronto‘s department of Medical Biophysics and Molecular Genetics.

Mr. Sym-Smith is attending the Emerging Medtech Summit to identify new investment opportunities and scout the future of medtech.

David Sym-Smith, is a Partner at Mobility Ventures who is a 25 year mobile industry veteran with a solid record of building multi-million dollar operations from scratch along with profitable exits.  Most recently, David served as Interim CEO at IndoTraq, the developer the fastest and most precise wireless indoor 3-D tracking system.

David has served as senior executive of global corporations as well as at multiple startups. He has a proven record of success in launching new markets, turnarounds, starting new business groups, building sales channels, introducing new products and services, winning market share and exceeding revenue and sales goals. 

Prior to joining Mobility Ventures, David served as the Chief Strategy and Marketing Officer of Tele Atlas. David managed global marketing, strategic planning, and product development for this leading global provider of digital maps and location content. Company doubled in size and was sold to TomTom for over $3 Billion.  Previously David served as the SVP of Global Business Development and Marketing at InnoPath, where he managed global marketing, product development and business development for InnoPath the industry leader in over-the-air (OTA) software updates and mobile device management (MDM) solutions. He Increased market share to 70% and revenue by more than 100%. David also helped launch Command Audio Corporation as Senior Vice President of Global Sales and Marketing, successfully leading the company from beta to launch to spin-off,  growing the company from 20 to over 100 people with over $80M in funding from Tier 1 VC’s and strategic investors (partially acquired by iBiquity).

David was a member of the founding core management team of Aerial Communications, serving as Regional President; he helped grow the organization from a mobile telecom start-up from early pre-launch phase, to a large entity with a $1.1B market cap within one year and was sold thereafter for more than $3.0B to T-Mobile (VoiceStream). At Sprint Spectrum he led Marketing and Product Development in launching the first PCS network in the country and first GSM network in the Americas.  Helping build a startup into an 800-employee, $150M revenue business in only the second year of service, and exiting with Sprint PCS’s purchase of operating control

David has also held senior management positions at CellularOne, AT&T, GTE, Saint-Gobain (France) and The Hay Group. He holds an M.B.A. from Pennsylvania State University – Smeal College of Business.

Simon joined Sofinnova in 2021 after consulting for Corporates seeking to develop partnership with Digital Health companies. He worked closely with business development functions to identify, assess, and structure strategic investments. Prior to that, Simon was at Baxter International, where he was part of the External Innovation Department. At Baxter, Simon coordinated scouting activities and technical due diligence that assessed M&A opportunities.

He is a Board member at Gradientech AB, a privately held Swedish company developing ultra-rapid treatment decision tools for antibiotic susceptibility testing. He is also a Steering Committee member of the MedFIT conference, an international event that brings together key innovators in the MedTech, diagnostic and digital health sectors.

Simon enjoys constant exposure to novel technologies, curious and motivated people, and supporting the development of companies that are striving to improve medicine. He decided to join Sofinnova because of the strong team spirit and collective drive.

He has a B.Sc. in Biomedical Science from King’s College London and an M.Sc. in International Business from SKEMA Business School.

Bio coming soon.

Bio coming soon.

Christian Snyder earned his BA in Finance and Investing from the University of Tennessee at Chattanooga while playing middle linebacker. Using two more years of eligibility, he now pursues an MBA with a concentration in data analytics, with plans to study for the CFA. Since joining Solas, Christian has provided expertise about the SPAC markets and financial analytics of current portfolio companies.

Bio coming soon.

Bio coming soon.

Joshua Eckelberry graduated with honors from East Tennessee State University with a BS in Biochemistry as a Mayme Frazier Scholar and then attended Quillen College of Medicine for two years on the nationally ranked rural health track before diverting to pursue an MBA in Healthcare Administration. While in school he pioneered Quillen's anatomy lab internship where he helped create the school's first digital dissector, served as president of the local American Medical School Association, helped negotiated a hospital staffing contract worth over $1M, and raised over $200K for area non-profit clinics. With his understanding of both the science and business sides of the life science industry, Josh helps translate and negotiate the optimal outcome for patients and the companies. Josh has a lifelong commitment to drive positive impact on the community and the world through leveraged change.

Bio coming soon.

Dave has worked with the partners of Solas BioVentures since 2004 and was a founding member of the firm in 2014. He currently focuses on investments in medical device and therapeutic companies. Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care, Dave is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. Dave recently retired from his position as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine.  Dave also retired from clinical practice after a 30 year career. Dave received a BS in Biology from Morehead State University, where he is Hall of Fame member, is a recent graduate from University Tennessee Chattanooga with his Master of Business Administration with a concentration in Healthcare and earned his medical degree from the Joan C. Edwards College of Medicine at Marshall University in 1990. He completed residency at the University of Florida Health Science Center and Fellowship training at Wake Forest University.

Bio coming soon.

Bio coming soon.

Bio coming soon.

David has over 35 years of experience in corporate management, audit and finance, the last 25 years in the MedTech sector. He is an experienced MedTech investor and entrepreneur. He has invested in over 20 MedTech companies and co-founded and managed several European MedTech distribution companies over the past 23 years, including Regis Medical GmbH, Ovum Ventures GmbH (sold to Medtronic 2009), and Cardiologic GmbH (sold to Boston Scientific in 2002). Following Boston Scientific’s acquisition of Cardiologic GmbH, he served as Finance Controller for Boston Scientific in Germany, Austria and Switzerland. Prior to joining Cardiologic GmbH as Co-General Manager in 1996, David was the CFO of Chiron Adatomed GmbH, a German subsidiary of Chiron Corporation (NASDAQ: CHIR). Prior to that, he worked in Ernst & Young’s Munich office, advising on corporate M&A transactions. David holds a degree in Accountancy from the University of Birmingham, UK and is a member of the Institute of Chartered Accountants in England & Wales (ACA, ICAEW).

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Ryan was trained in genetics and cell biology at the University of California at Davis. Since 1988 he has worked in several biotechnology companies and as an independent biotech consultant focused on adding value to early stage therapeutic and technology efforts. Early in his career Ryan worked in teams that applied cutting edge genetic engineering technologies to advance the development of gene therapy and cellular therapeutics.

In 2002 Ryan transitioned to research and product development for biopharmaceutical instrumentation, where he held customer-facing positions related to the introduction of novel technologies. In this role, Ryan grew to be a recognized expert in label-free biosensors, presented at numerous international scientific conferences, and was invited to chair several scientific symposia. Ryan is co-inventor of five US patents, has published multiple scientific communications, developed many applications for the drug discovery market, and lead collaborations worldwide with well-known pharmaceutical research teams from companies like Merck, Amgen, J&J, Novartis and AstraZeneca.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Rob is a Partner at Endeavour Vision focused on investments in medical technology, digital health and diagnostics. Rob represents Endeavour Vision on the boards of Kestra Medical Technologies, Virtual Incision Corporation, InBrace, Willow and Nalu Medical. He serves as a board observer for IntelyCare, and was on the deal team for the investment in Rapid Micro Biosystems.

Rob joined Endeavour Vision after 15 years at Boston Scientific, which has been one of the most active acquirers in medical technology in recent years. In his role as Vice President, Corporate Business Development, Rob was responsible for leading the identification, assessment and execution of Business Development transactions for Boston Scientific’s Interventional Cardiology, Peripheral Intervention and Rhythm Management divisions. This included acquisitions, divestitures, minority investments and joint ventures.

Prior to his Business Development role, Rob held leadership positions in commercial strategy and marketing at Boston Scientific. Rob also previously worked at The 3M Company where he was an Engineering Project Leader.

Rob holds a BS in Chemical Engineering from Northwestern University and an MBA and a Masters in Engineering Management from The Kellogg School of Management.

Bio coming soon.

Bio coming soon.

Robert J. Greenberg, M.D., Ph.D., is the Chairman and CEO of the Alfred Mann Foundation. He was a co-founder and former CEO and Chairman of the Board of Second Sight Medical Products, Inc. (NASDAQ: EYES) in Los Angeles, California. Dr. Greenberg is a leader in the field of neural prosthetics – having developed and brought to market the world’s most advanced implantable neural stimulator, the Argus II visual prostheses, to treat retinitis pigmentosa, a form of blindness. Dr. Greenberg was also a medical reviewer at the FDA’s Office of Device Evaluation. Dr. Greenberg is the recipient of numerous honors and awards, has over 260 issued US patents and over 100 international patents, and has published over 60 articles. He received MD and PhD degrees from The Johns Hopkins School of Medicine in Baltimore, Maryland. Dr. Greenberg joined AMF in 2004 as Chairman of the Board of Directors.

Bio coming soon.

Edward Hanlon joined Gilde Healthcare in 2020 in the Cambridge office and focuses on Healthtech.

Prior to joining Gilde, Edward worked in advisory for Health Advances, a consulting firm operating across healthcare sectors in medical devices, biopharma, health technology, and diagnostics. He has broad experience in commercial strategy and M&A due diligence, advising a range of clients including late-stage start-ups, multinational corporations, and financial investors. Since joining the Gilde Healthcare, Eddie has contributed to several investments, including Eargo, Spire Health, and Nalu Medical.

He has a B.S. in biology from Duke University. During his undergraduate years, he worked as a research assistant at the Duke University Center for Cognitive Neuroscience and the Liberty Mutual Research Institute Center for Behavioral Sciences. Edward is a US citizen.

Kristin Havranek has worked extensively with and in the MedTech industry for the last 25 years. A trusted advisor to investors and companies alike, Ms. Havranek regularly helps startup and emerging MedTech companies build their IP portfolios in a strategic, thoughtful manner with their business goals and needs in mind. She evaluates freedom-to-operate, patentability, investor due diligence and financing IP, and conducts patent validity analyses. She advises on strategic alliances and prepares and prosecutes patent applications before the U.S. Patent and Trademark Office. Ms. Havranek’s ties in the industry run deep and is currently on the leadership team of MedtechWomen.

Ms. Havranek’s background as a Biomedical engineer in industry, most recently as a Senior Engineer at Guidant Corporation, and as a MedTech attorney advising companies in a wide variety of technological areas makes her uniquely qualified to find the path to successful IP protection and value creation for your MedTech company.

James Huie is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati's San Francisco office, where he has one of the most active practices in the country representing venture-backed companies. He advises life sciences and technology companies on general corporate matters, mergers and acquisitions, initial public offerings, strategic partnerships, and private equity and debt financings. He also has extensive experience in representing venture capital firms and other investors in private equity and debt financings.

James also serves on the investment committee for the firm's affiliated fund, the WS Investment Company.

Bio coming soon.

Bio coming soon.

Mr. Julian’s role involves supporting investment decisions, portfolio company management and investment outcomes. He evaluates potential new portfolio company targets with emphasis on bottom-up valuation analysis and deal structure. In addition to these responsibilities, Mr. Julian is a member of the Firm’s research team, participates in its Investment Committee meetings and is regularly evaluating thematic industry opportunities.

Prior to joining the firm, Mr. Julian was an analyst at the hedge fund Round Table Investment Management, LLC where he was the youngest member of the firm’s investment committee. His duties included security analysis, industry assessments and derivatives trading. Prior to joining Round Table, Mr. Julian played on the Men’s Varsity baseball team at Brown University.

As founder and head of Intuitive Ventures, I'm passionate about accelerating the future of minimally invasive care by investing globally in transformative early-stage startups across digital health, medtech, therapeutic and diagnostic domains.

Sabing H. Lee's practice includes strategic patent procurement, patent portfolio management, intellectual property due diligence and general counseling on infringement, licensing, international IP protection and post-grant proceedings. Sabing currently represents clients in a wide range of technologies, with an emphasis on medical devices and procedures and materials science. 

Sabing co-chairs the firm’s Medical Devices and Procedures group. In the medical device field, Sabing has worked extensively with cardiovascular, orthopedic, wound care and healthcare AI technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge, Inc. (acquired by Medtronic, Inc.), Flex-Foot, Inc. (acquired by Össur hf.), Endius, Inc. (acquired by Zimmer Holdings, Inc.), ev3 Inc. (acquired by Covidien), CardiAQ Valve Technologies (acquired by Edwards Lifesciences), and Tornier/Wright Medical (acquired by Stryker). 

Sabing currently serves on the Board of Directors for Octane, an organization that drives technology industry growth and innovation in Orange County by connecting ideas and people with resources and capital. 

Sabing has been recognized as a Patent Star in Managing IP's "IP STARS" guide for his outstanding intellectual property legal work in 2018-2021. He has received "Star" recognition in the "Life Sciences Survey" published by Legal Media Group (LMG) Life Sciences from 2012-2017. He was noted as being among the top patent strategists in the country for his patent prosecution, patent advisory, strategy and management practice. Sabing was selected for inclusion in the "Southern California Super Lawyers" list for his work in intellectual property law from 2013-2018 by Super Lawyers magazine, and was named to the Daily Journal's list of the "Top Intellectual Property Attorneys of 2014", where he was recognized among the Top 25 Portfolio Managers & Patent Prosecutors of Intellectual Property.

Sabing joined the firm in 1997 and became a partner in 2003.

Bio coming soon.

Bio coming soon.

Alexander is a Partner at Endeavour Vision, investing in medical technology, digital health and diagnostics companies across multiple therapeutic areas.

Alexander brings more than two decades of business and strategy experience in both medical device and high-technology companies. He currently represents Endeavour Vision on the boards of Kenbi, Relievant MedSystems, Lumeon, Rapid Micro Biosystems (NASDAQ:RPID) and VentureMed, and led the firm’s investments in Gynesonics, Nuvaira and V-Wave. He previously served on the boards of VertiFlex (acquired by Boston Scientific in 2019) and EndoStim. He is a member of the steering committee for PCR Innovators’ Day and serves as both a jury member and expert panelist for the Healthtech Summit.

Prior to joining the Endeavour Vision team, Alexander spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy and McKinsey & Co.

Alexander holds an MBA from INSEAD and a BSFS, magna cum laude, from Georgetown University

Collaborative leader known for results-driven, hands-on business partnership and problem solving.
Strategic thinker with a passion for utilizing strong analytical skills to challenge and improve the status quo, and a track record of delivering results with integrity and an attention to detail. Highly accomplished professional with experience in driving strategic top-line growth and profitability.

Matthew's professional experiences include work in business development and M&A, corporate finance, valuation and modeling, market strategy, tax strategy and planning, and equity research.

Specialties: M&A Experience; M&A Due Diligence; Strategic Planning; Business Strategy; Financial Modeling; Capital IQ; Microsoft Office: Word, PowerPoint, Excel, Visio, Access; Cognos; SAP; Corptax; Accounting; Financial Analysis

Matt Wetzel is an experienced health care fraud and abuse and compliance lawyer. He provides strategic advice to life sciences companies on complex health care laws and regulations, including federal and state fraud and abuse laws, billing and reimbursement regulations, and transparency requirements, among other areas. Mr. Wetzel also establishes and aids clients in operating effective compliance programs.

Mr. Wetzel brings a unique, 360-degree perspective of the legal and compliance issues affecting life sciences companies. As a veteran of the medtech industry, he brings a pragmatic approach to counseling his clients. Prior to joining Goodwin, Mr. Wetzel served as Chief Compliance Officer of a Silicon Valley biotech start-up; was the Vice President & Deputy General Counsel of the world’s largest medical technology trade association in Washington, DC; and held an executive legal role at a multinational medical device maker.

Dr. Nick Pliam joined Decheng Capital at its inception in 2011 and is based in its Menlo Park office. Trained as an orthopedic surgeon and endocrine physiologist, he leverages a combination of scientific, clinical, entrepreneurial and investment experience to build and support life science companies. He currently serves on the boards of CardiMED, Centricity Vision and Polares Medical.

Dr. Pliam was previously a venture partner at Bay City Capital, serving on the board of Nevro (NYSE: NVRO), which was incubated at Bay City to become a global leader in neuromodulation for chronic pain management. He was also a board member of Aragon Surgical (acquired by Aesculap) and IDev Technologies (acquired by Abbott). Dr. Pliam has served as an advisor to several pharmaceutical and medical technology companies, and as managing director of a New York-based boutique investment banking firm. He co-founded of Pharmagenesis, which focused on drug discovery from natural products, and Guided Delivery Systems (now Ancora Heart).

Dr. Pliam earned his undergraduate degree in German Literature from the University of California, Berkeley, completing year-long studies at Georg August Universität in Göttingen, Germany. He received his MD from Dartmouth Medical School and PhD in Endocrine Physiology from the University of California, San Francisco. Following general surgery residency at UCSF, he completed orthopedic surgical residency at the Stanford University Medical Center. He was a staff physician in orthopedic surgery at the Palo Alto Medical Foundation and Stanford Medical Center.

Anthony Williams joined HealthQuest in 2019. Before joining HealthQuest, Anthony spent eight years at Globus Medical, Inc. (NYSE: GMED), a multinational medical device company focused on developing products that promote healing in patients suffering from musculoskeletal disorders. He served in a variety of leadership roles during his tenure at Globus and ultimately spent the last 3½ years as President of the company. He currently serves as a board member on portfolio companies ENT Specialty Partners and 83bar, and as an observer for Magnolia, TigerConnect and Trice.

Prior to joining Globus Medical, Anthony was a partner with Wyrick Robbins Yates & Ponton LLP, a law firm based in Raleigh, North Carolina, where he specialized in corporate and transactional work for high growth life sciences companies and their investors, including public and private financings, mergers, acquisitions and other strategic transactions, and corporate governance matters. 

Throughout his career, Anthony has been a frequent speaker to entrepreneurial groups, such as the Durham, NC-based Council for Entrepreneurial Development. He previously served on the board of directors of SEBIO and is currently a mentor to entrepreneurs through the Philadelphia-based Mentor Connect, a program sponsored by Ben Franklin Technology Partners and the Philadelphia Alliance for Capital and Technologies (PACT), and Austin-based Texas Health Catalyst, a collaborative initiative of Dell Medical School and the University of Texas at Austin,  both of which provide much-needed mentoring to inventors and entrepreneurs.

Anthony holds a B.A. degree from the University of North Carolina at Chapel Hill and J.D. and M.B.A. degrees from Wake Forest University. 

Anthony lives in Austin with his wife and two sons, with whom he enjoys hiking and traveling.

Dr. Baker began his med-tech career as a physician and has worked for over 18 years as an emergency physician at UCSF Benioff Children’s Hospital.  He is board certified in Pediatrics and Pediatric Emergency Medicine and has special research interests in brain injury and pulmonary disease.  He founded his first company over nine years ago in the ENT therapeutic and diagnostic space and has since been also consulting for other start up medical device firms.  He joins Aphelion Capital as a Clinical Partner and continues to do clinical work as well.

Dr. Baker sits on the board at Aardvark Medical and Colabs Medical. 

Prior to Ajax, David was an associate at Latham & Watkins LLP, where he advised emerging companies and VC and PE firms on corporate governance issues, equity financings, and M&A transactions.  Before Latham, David served as a judicial law clerk to Chief Justice John Roberts (U.S. Supreme Court), Judge Brett Kavanaugh (U.S. Court of Appeals), and Judge Dabney Friedrich (U.S. District Court), and as a judicial extern to Judge Mark Wallace (U.S. Bankruptcy Court).

David received his J.D. from Harvard Law School, where he served as editor of the Harvard Law Review and graduated first in his class, summa cum laude.  He received his B.S., summa cum laude, from the University of Southern California.  Before law school, David led business development for The Drop Box, a documentary film that has raised over $10 million for children with disabilities through strategic partnerships and worldwide distribution.

Ronnie has more than 10 years of medical device project management and R&D management experience in both Chinese and American medical device industry. Now serving as the Partner of Mednovation, Co-founder of ONE investment club and Access technology. Recent deal includes Innovheart, Xeltis, Merion etc. Before investment banking, Ronnie was focus on R&D project and program management in both US and China Medtech companies. He had been engaged in several innovative projects including: Heart Valve stent, Drug eluting stent, inferior vena cava filter, Stent retriever and Flow diverter.

Ronnie owns more than 10 patents in biomedical engineering. He holds California professional engineer license. He has a MSc. In Bioengineering specializing in medical device from San Diego State University.

Prior to Ajax, Cason received his J.D. from Harvard Law School, where he served as editor and Business Chair of the Harvard Law Review, participated in the Harvard Innovation Lab venture incubation program, and graduated magna cum laude. Prior to law school, he was an account manager at Oracle, covering data security solutions.

He received his B.A. from Stanford University.

Bio coming soon.

Jeff Peters is a Venture Partner with OrbiMed. Mr. Peters has over 25 years of medical device experience and currently serves as the President and Chief Executive Officer of Cardialen. From 2014 to 2017, Mr. Peters had several financial and operating consulting roles in public and private companies. Previously, Mr. Peters was the Chief Executive Officer of Anulex Technologies, a company developing minimally invasive spine therapies; he also served as the Chief Technology Officer of ev3 (now Medtronic) from 2001 2007. Mr. Peters’ prior financial roles include Portfolio Manager at Black River Asset Management, Entrepreneur in Residence at Foundation Medical, and Stock Analyst at Dain Rauscher Wessels. Mr. Peters received his B.S. and M.B.A. from the University of Minnesota.

Bio coming soon.

Bio coming soon.

Seasoned, results-driven leader experienced in identifying, launching, spinning-out, funding, building, scaling, and turning-around opportunities in healthcare and technology; strategy; operations; partnering; commercialization; and exits. Experience from roles including founder, VC, CEO, Board Chair, counsel, and advisor. Specialized in start-ups; enterprise incubation/creation; venture finance; developing/supporting early-stage and growth-stage ventures; turnarounds; and special opportunities.

Venture Capital/Private Equity: Knowledge from all sides of the table: generating/evaluating deal-flow; investing; building/managing companies/portfolios; structuring, positioning, leading, and executing financing, strategic, and exit transactions.

Leadership: Strategic planning/implementation, financial management, organizational/team development, mentoring, creating/aligning incentives, IP strategy, regulatory strategy, reimbursement, compliance, risk management, partnering, and structuring/executing financing, strategic, and exit transactions.

Technologies/Services: Domain expertise identifying, developing, financing, and commercializing healthcare, biomedical, IT, and convergence technologies; developing, implementing, and managing concepts, structures, programs, and alliances for healthcare delivery, management, infrastructure, service, support, and payment, including population health, ACOs, global risk, and MSOs.

Board Experience: Healthcare, technology, and other areas. Lead/mentor management/boards to develop/implement structure, process, and culture for teamwork, transparency, accountability, and performance.

Bio coming soon.

Suraj Mudichintala is a senior associate at APVC in Palo Alto, CA. He represents APVC on the Boards of Alpheus Medical and Axon Therapies. He was previously an investor at Arboretum Ventures, where he served as a Board observer at Allay Therapeutics, Avation Medical, Francis Medical, Health Scholars, Koya Medical, and RareCyte. Prior to investing, Suraj was an associate with L.E.K. Consulting, a global strategy consulting firm. While at L.E.K., Suraj completed ~20 engagements predominantly for life sciences and private equity clients.

Suraj graduated cum laude with a B.S. in Finance and Analytics from Boston College. Suraj previously served on the Michigan Translational Research and Commercialization (MTRAC) Oversight Committee for Medical Devices, where he provided guidance to Michigan higher education researchers on transitioning their early stage products to the private sector for commercialization.

Bio coming soon.

Bio coming soon.

Business leader with a proven track record in growth organizations. Experienced in creating and leading high performing teams, designing go to market plans and delivering exceptional results

Recruit, motivate, and lead highly effective sales teams. Quickly assess organizational needs, identify and recruit skilled teams to execute and exceed plan.

Experienced in large multinational companies, post launch start up as well as pre launch start up organizations.

Work cross functionally with all areas of an organization, finance, product development, engineering, marketing, etc. to ensure alignment and exceed revenue and profit goals.

Bio coming soon.

Bio coming soon.

Over 25 years of experience in the life sciences industry focusing on focusing on advising companies in all facets of corporate development. Mark’s experience spans major areas of life sciences including large molecule, small molecule, drug delivery, diagnostics, medical device firms, digital health, and healthcare distribution. Mark’s has led client engagements in North American, Europe, and Asia.

M&A professional providing financial due diligence services in the med tech and life sciences sectors. My primary fields of expertise include (i) buy-side transaction advisory for strategic and private equity clients, and (ii) full enterprise sales for private equity clients and carve-out / spin transactions for strategics.

Bio coming soon.

Bio coming soon.

Tom Daulton brings over 30 years of healthcare leadership experience to Veranex, joining from National Dentex Labs (NDX), where he served as chairman and CEO for the past seven years and built one of the largest dental lab networks in North America. His additional experience includes key roles at medical device and healthcare services organizations with global scale, including 20 years at Baxter, Allegiance Healthcare, and Cardinal Health. Daulton was also founder and CEO of Devicor Medical Products, which acquired Mammotome’s breast care business from Johnson & Johnson’s Ethicon Endo-Surgery. The addition of Daulton will further expand extensive device experience across the Veranex executive suite.

Strategy and business development leader with scientific training and demonstrated success in working with multi-disciplinary teams to source, evaluate and develop innovative biomedical technologies that satisfy unmet clinical needs. Passionate about mentoring entrepreneurs motivated to make an impact in the healthcare space.

Experienced in technology and business development, project management, due diligence, primary market research, financial analysis and mapping out regulatory and reimbursement strategies for biomedical products.

Bio coming soon.

Bio coming soon.

Dr. Stout’s career includes business, government, and nonprofits, as well as the UN and academia. He’s traveled the world, published 38 books, won a wide range of accolades, including four additional doctorates (honoris causa), and invitations to TEDs, Davos, Renaissance Weekends…

He’s is a licensed clinical psychologist and Founding Director of the Center for Global Initiatives, a Top Rated Healthcare Nonprofit. His entrepreneurial experience is demonstrated in multiple start-ups and serving as an advisory board member, and early-money-in investor. He's been faculty in the University of Illinois' College of Medicine and Northwestern's Feinberg School of Medicine. He served at the UN and was appointed to the World Economic Forum's Global Leaders of Tomorrow and an Invited Faculty at Davos. He is the founder of GordianKnot, LLC, and is Emeritus VP of Clinical Research and Data Analytics at ATI.

Dr. Stout is a Fellow in the APA, past-President of the IPA, and is member in the National Academies of Practice. He is a best selling nonfiction author whose works have been translated into 8 languages. He has been awarded with 4 Humanitarian Awards and is in 3 Halls of Fame.

He has served as C/E/O/I/Officer. He has traveled to over 100 countries and founded a kindergarten in Tanzania. He is listed in TED-Founder Richard Saul Wurman’s “Who’s Really Who 1000: The Most Creative Individuals in America.” Purdue has named a scholarship in his honor.

Dr. Stout was educated at Purdue, University of Chicago, and Forest Institute, gaining over 24 awards and 4 scholarships and was Valedictorian of his doctoral class. He was a Postdoctoral Fellow at Harvard Medical School. He has been awarded over 40 other postdoctoral awards. He has been interviewed on CNBC, CNN, NBC, PBS, NPR, Oprah, Time, Chicago Tribune, Wall Street Journal, New York Times, USA Today, and others. He's an amateur alpinist, ultra runner, and diver. Full bio and portfolio: https://linktr.ee/drchrisstout Wikipedia: https://en.wikipedia.org/wiki/Chris_Stout_(psychologist)

Amanda DePalma joined FUJIFILM Sonosite, Inc. in December 2019 as Vice President of Marketing. In her role, Amanda has global responsibility for all marketing aspects of our business. Amanda brings over 25 years of experience in marketing, strategy, and sales at companies including Guidant, Abbott Vascular, Kimberly-Clark Healthcare, and Edwards Lifesciences. She has led high-performing teams in the development and launch of over 30 products and solutions. Amanda's healthcare experience spans multiple clinical areas with an emphasis on cardiology, vascular, surgical, anesthesiology and critical care. Amanda is passionate about fostering diversity in the workplace, and is actively involved in MedtechWomen and the AdvaMed Women's Executive Network. She received her BS in Marketing and MBA from the University of Florida.

Bio coming soon.

In this role, Matt oversees all phases of the M&A process, from deal sourcing to execution.

Matt joined the Corporate Development team in 2015 and has managed numerous global M&A scale transactions, various tuck-in acquisitions, late-stage technology deals, and distributor-to-direct conversions.

Prior to joining Teleflex, Matt worked in the Audit and Enterprise Risk Services and M&A Transaction Services groups at Deloitte & Touche.

Matt is a CPA and has a Bachelors' degree in Business Administration from the Goizueta Business School at Emory University.

He is based in Wayne, PA, USA.

Bio coming soon.

Dan has served as a principal, director, and advisor to early-stage and mature companies in the real estate, applied technology, and energy sectors. His areas of focus include green energy and resilient development. With a background in structured finance and complex transactions, Dan works directly with our portfolio companies and prospects to evaluate business opportunities and structure fund investments. A licensed attorney who formerly practiced at the global law firm DLA Piper, Dan received his BA in Economics from Swarthmore College and JD from the University of California Hastings College of the Law. Dan’s professional affiliations include the US Green Building Council and Urban Land Institute. Outside of work, while not spending time with his wife and four children, Dan can be found attempting stupidly uncomfortable and physically demanding challenges in inhospitable parts of the world.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

A partner (principal) since 1998, Glenn is living his "dream job"​ leading Deloitte's MedTech practice (devices, diagnostics, supplies and clinical/research tools) as it combines his roots as a mechanical engineer with his early consulting experience leading hospital clinical transformation programs. The med tech sector is positioned to be a substantial transformational force for the healthcare industry, harnessing the power of exponentials through sensor technology and augmented intelligence. However, it must adapt to new buying processes, higher "value" expectations, and a changing global regulatory and reimbursement environment.

A selection of Glenn's articles and whitepapers can be found at http://www.deloitte.com/view/en_US/us/Industries/1d4083c4abefd110VgnVCM100000ba42f00aRCRD.htm

Investment professional with 15+ years experience executing in business, technology, and regulatory sides of organizations ranging from Fortune 500s to start-ups to government agencies.

Currently focused on early-stage investments in medical devices, diagnostics and life sciences on behalf of 13 health systems and 462 acute care facilities across the U.S.

Commercial loan portfolio and relationship manager; structuring, underwriting and monitoring of credit facilities; Advanced quantitative, analytical and market research skills; Comprehensive financial data and business structure analysis; Extensive project management; marketing and investor relations; Fluent in English, Russian and Hebrew.

Lisa is a senior relationship manager and strategic business partner with outstanding financial awareness and relationship management capabilities honed through extensive experience in the banking industry.

Bio coming soon.

Builds partnerships with biotech, diagnostic and medical device companies throughout Southern California as part of the national Commercial Banking team dedicated to the Life Sciences industry.

https://www.jpmorgan.com/commercial-banking/industries/life-sciences

Bio coming soon.

Bio coming soon.

Experienced Investment Banking Associate with a demonstrated history of working in the financial services industry. Skilled in Corporate Finance, Financial Modeling, Securities, Equities, Mutual Funds, and Asset Allocation. Strong professional with a Master of Business Administration (MBA) focused in Accounting, Finance, and Strategic Management from The University of Chicago Booth School of Business.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Accomplished healthcare executive with over two decades of sales and business development experience. Proven track record of providing executive leadership and generating financial results. Established and managed high performing teams via a cross functional, data driven approach. A diverse background that spans business development, client management, sales, consultant relations, organizational development, sales operations, data analytics and healthcare management consulting. Primary focus is to help companies achieve profitable growth and mutual value creation.

Joshua currently serves as Growth Officer within Fitbit Health Solutions where has oversight of enterprise initiatives and strategy across health plans, health systems, partners, government and research entities.
Prior to joining Fitbit, Joshua held leadership positions at Progyny and WebMD Health Services where he helped drive double-digit revenue growth. Joshua has a degree in Behavioral Science and Law from the University of Wisconsin, Madison, and completed executive courses at Columbia Business School.

Health and wellness expert, speaker, author and leader who created, implemented, directed, managed and evaluated a broad range of health programs over the past 18 years. Experience with a diverse number of organizations including manufactures, universities, service industries, school corporations, health systems, and health plans. Specialize in consumer experience and well-being solutions that allow for strong strategic qualities that drive business results and brings forth a unique consumer centric experience. Skilled in market analysis and research within healthcare and well-being industry that drives new solutions and consumer experiences with higher engagement, increased total sales, and execution towards organizational goals.

My dedication, passion and enthusiasm for health and wellness, drives me daily to bring forth consumer experiences that allow each individual to be at their best.

• Specialize in multi-channel solutions for consumers and clients that provide choice and personalized options in improving overall health and well-being, leading to higher engagement rates and health outcomes.
• Developed, launched, implemented and operated total population management and stand-alone wellness offerings for employers and health plans, launching 12 unique platform solutions for health plans and wellness organizations.
• Over 6 years of experience in Agile development processes and over 15 years of experience in traditional development processes.
• Leading diverse teams to align to core organization goals and driving the team to exceed goals to support organization growth.

Bio coming soon.

Susan is a Partner at Health Advances, LLC, a strategy consulting firm focused on the healthcare industry where she co-leads the Medtech Practice Group. During her 20 years at Health Advances, Susan has worked on over 250 project engagements, with a wide variety of clients ranging from small start-ups to some of the largest public companies in the industry. Susan’s work with these companies has helped to optimize the value of products and technologies through extensive market evaluations, due diligence of M&A opportunities, and the development of strategies for sales and marketing efforts. Susan has extensive experience in the device sector, including minimally invasive and interventional products. Susan’s expertise includes women's health, urology, critical care and other hospital-based and physician office technologies. Susan has published articles in a number of industry journals including a Medtech Insight article focusing on the value proposition for medtech products and is a previous MassMEDIC board member.

Prior to joining Health Advances in 2000, Susan worked at Interneuron Pharmaceuticals, Inc. in the areas of business development, marketing, and product management. Susan’s high technology experience also includes Molten Metal Technology, Inc. Susan earned her BA in General Science with a minor in Business and Managerial Economics from Brandeis University.

Tracy Walters is a Partner in the Medtech Practice Group at Health Advances where she has worked on over 250 project engagements with a wide variety of clients ranging from small start-ups to some of the largest public companies in the industry. She partners with clients to develop growth strategies for medtech products across sites of care including hospital and physician office, and has extensive experience in many therapeutic areas including neurology, ophthalmology, and cardiology.

In 2019, Tracy summited Mount Everest, a feat accomplished by fewer than than 650 women in the world at the time.

Accomplished business development professional accustomed to building contacts and relationships in completely new areas. Provides client a 'Voice' during process to insure their needs are addressed and met. Helped develop client retention strategies to improve satisfaction and assure repeat business opportunities.

Rak Mehta is a founding member of the Medtech practice at Centerview Partners.  He has over 25 years of experience as a strategic advisor to life sciences management teams and boards across medical device, diagnostics, and tools, and biopharma companies.  Over the course of his career, Rak has engaged with clients on a broad range of complex strategic transactions, buy-side and sell-side mergers and acquistions, divestitures, debt and equity financings and partnerships.

Bio coming soon.

Coming Soon.

Experienced founder CEO with a demonstrated history of working in the medical device industry. Skilled in Management, Start-ups, Financing and Leadership. Strong business development professional with a Master of Business Administration (M.B.A.) from Harvard Business School and B.S./M.S. in Mechanical Engineering from Carnegie Mellon University. 2021 Forbes Next 1000.

I serve as Partner for CRG, a premier healthcare investment firm that has raised and committed more than $3 billion of institutional capital across three funds to date. As a student of healthcare, I believe in developing smart financing solutions for improving patient outcomes, reducing costs and creating more personalized medicine. In my current role, I lead CRG’s investment process from sourcing and due diligence through realization and am responsible for portfolio management and portfolio company exits.

Coming soon...

24+ years of design experience developing medical and consumer products.

Strategic leadership, management, and creative development of numerous products in a variety of industries and markets.

Marketing and business development executive with extensive experience in strategic marketing, sales leadership, business development and R&D engineering within organizations ranging from mid-tier private equity owned to $30B matrixed global organizations. Proven track record for developing and launching products that drive top line revenue while improving bottom line profitability.

Passionate about accelerating new ventures, Nic brings 15 years of experience in leadership and advisory board roles. He has worked with companies including Medtronic, Abbott, and Philips on Product and Business Development strategy and Venture investment.

He has also advised and supported several startups in their growth, development and financing preparation.

Nic graduated with a MSc and PhD in Engineering from Imperial College London. He started his career working with Healthcare organisations including Imperial College and then NHCS Singapore as PI for Medtech Innovation. He has authored multiple patents and over 150 publications, receiving several awards for his contribution in cardiovascular innovation. He is also adjunct Associate Professor at the Duke-NUS Medical School in Singapore.

He is currently Deputy Managing Director at Medinbox, a leader in connectivity solution for medical education and remote support. He serves on the executive board of CoreAalst, a clinical research incubation company, and with DHENIN, his mission is to bring to market and accelerate disruptive value propositions that reduce costs and inefficiencies.

Investor in medical devices, life science tools, diagnostics, and digital health. Feel free to drop a line if you’re an entrepreneur or investor in any of these spaces.

Hank Kucheman serves as a Senior Advisor or Board Member to various public and private medical device and health care companies. Kucheman previously served as Chief Executive Officer for Boston Scientific, focused on leading global markets for less-invasive medical devices.

Before being named CEO in October 2011, Kucheman was Executive Vice President and President of the Cardiology, Rhythm and Vascular (CRV) Group and was responsible for the Company’s Interventional Cardiology and Cardiac Rhythm Management businesses and its Endovascular Unit, which includes the Peripheral Interventions, Neurovascular, Imaging and Electrophysiology businesses.

Before joining Boston Scientific, Kucheman held a variety of management positions in sales and marketing for SCIMED, Charter Medical Corporation and Control Data Corporation. He began his career at the United States Air Force Academy Hospital and later was Healthcare Planner, Office of the Surgeon General, for the United States Air Force Medical Service.

Kucheman earned a B.S. and M.B.A. from Virginia Polytechnic Institute and State University. He has served on several industry boards, including the board of directors of the Global Health Exchange.

I have more than 20 years of experience in the medical technology industry. My expertise is in sales and marketing and particularly in bringing innovative products and life changing technologies to market. I am passionate with new technologies and I love making a difference. I am highly result oriented and I believe that building high performing teams and developing people is essential to success.

My other passion is sailing for the challenges, the team spirit and to recharge.

Bio coming soon.

After completing an MBA at the Yale School of Management, New Haven, CT, in May 2014, I decided to leave the practice of medicine. I am fortunate to be able to utilize my knowledge of business and healthcare in my current role with Stryker Spine in Business Development. Prior to accepting a position with Stryker, I worked as a spine surgeon at the Montefiore Medical Center, Bronx, NY and held the title of Assistant Professor of Orthopaedic Surgery at the Albert Einstein College of Medicine, Bronx, NY. I am a board-certified orthopaedic surgeon with fellowship training in adult and pediatric spinal surgery.

Bio coming soon.

Bio coming soon.

Coming soon...

Experienced CEO, C-level executive and Board Member with a proven track record over 24 years. The focus of my career in healthcare has been in the commercialization and implementation of medical devices and advanced technologies. My organizational experience includes well-established multinational companies as well as start-ups. I focus on organizational development through implementing structure and process.

An entrepreneurial and disciplined executive with >20 years of CEO and C-level leadership experience in health care and a track record of success in innovating, financing and commercializing sophisticated medical technology. An adaptive leader and a quick learner who has delivered results in multiple settings. Deep relationships among the investment community, industry, the medical community and government stakeholders. Extensive public speaking and advocacy experience.

Coming soon...

Fellowship trained interventional radiologist practicing in a busy outpatient setting with expertise in ESRD, PAD, varicose vein treatment, interventional oncology and woman's interventions.

Coming soon...

A senior principal investor and healthcare innovation, corporate finance, business development and commercial strategy executive with over 23 years of multinational experience in Venture Capital, large pharma, early to mid-market stage bio/med tech companies, and investment banking. Over his career Andrew has established himself as a proven relationship builder and deal maker across all facets of the healthcare innovation continuum, from product concept development to launching best in class treatment modalities. During this time, Andrew cultivated a successful track record for building blue chip investor syndicates, growing businesses, and originating, negotiating, and executing pharmaceutical licensing, alliances/partnerships, and acquisitions that generated significant shareholder value and tangible financial returns.

Dr. James Wall is an Associate Professor of Pediatric Surgery at Stanford University who focuses on minimally invasive approaches to children’s surgery. He is an alumnus of the Stanford Biodesign program and holds a Masters degree in Bioengineering. He has a research focus on how we educate others to design and develop health technology as well as the emerging field of surgical endoscopy. He has developed multiple health technologies including a novel epidural needle, a protection device for umbilical catheters and a wearable leg compression system. James currently leads the perioperative Value Analysis Committee and surgical endoscopy program Lucile Packard Children’s Hospital. He is the Director of Program Development for the Innovation Fellowship at the Byers Center for Biodesign at Stanford.

Coming soon...

Coming soon...

Coming soon...

Innovative and proven commercial healthcare leader, experienced in strategy development, digital innovation, value-based contacting, reimbursement, and novel technologies. Successful history of developing and communicating economic value and financial impact of treatments and medical devices, for both start-ups and industry giants.

Executive/consultant to early to mid stage biotechnology, medical device and healthcare related companies on areas ranging from business/product strategy to financing. Have currently and in the past sat on the boards of several venture funded companies. Prior to my current consulting and venture projects, I was an independent analyst and consultant to institutional investors on areas ranging from satellite communications and biotech to software and new media. My research and opinions have appeared in many media outlets including Forbes, Wired, The Deal, CNN, American Banker, Barrons, Risk & Insurance Magazine, Smart Money, Reuters and Bloomberg. 

Bio coming soon.

Nishant has over 18 years of experience in medtech as an individual contributor and leadership role.

Currently leading the business development and investor relations at Synchron. Prior to Synchron, he has led R&D and Strategic Marketing team at medtech companies, such as LivaNova, Medtronic and Abbott.

Nishant received his Bachelor of Science in Biomedical Engineering from University of Texas at Austin and Master of Science in Electrical Engineering from Rice University. Recently, he completed the Stanford Biodesign Fellowship program at Stanford. 

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

• Over twenty years experience in new business development, strategic marketing, and major market expansions
• Proven to excel in a position requiring strong analytical and critical thinking skill, which inspire, motivate, and guide ongoing development to empowering high performing sales and marketing teams.
• Recognized Leader of Regional and National Divisions through process reengineering, and leadership development, which increased revenue and bottom line ROI from client relationships.
• Over ten years of demonstrated expertise in developing management tools to measure and analyze financial and operational information (e.g. business trends, financial forecasting, key performance indicators, integrated budget modeling, cost analysis, and management reports).
• Ranked #1 in the U.S. for Acute Care Division Business Development in 2015 with $.75M of Total Revenue.


Specialties: Business Development, Sales Management, Strategic Marketing, Management Consulting, Medtech Startup Consulting, Identifying Market Opportunities, Strategic Mentorship, Process Improvement

Bio coming soon.

Bio coming soon.

I am a Vice President in Private Equity / Venture Capital at OrbiMed. Prior to this role, I was a Vice President in Equity Research at Bank of America focusing on the Med Tech industry. Prior to Equity Research, I worked in the Healthcare group at Bank of America as an Investment Banking Associate. Additionally, I worked in management consulting with Accenture Strategy focusing primarily on Operations. I received my undergraduate degree from Vanderbilt University and my MBA from Emory University's Goizueta Business School.

Justin was born and raised in San Diego, California. While attending college in Los Angeles, he began working at a medical device startup as a regulatory affairs associate and experienced multiple 510(k) and CE Mark filings. After graduating, he joined Boston Scientific Corporation as a regulatory affairs professional and worked in both the US and Japan. During this time, he worked on nearly 20 submissions for products such as carotid artery stents, neurovascular embolization coils, and coronary stents.

Upon completing business school, Justin joined Johnson & Johnson in Japan as a part of the new business development team and was in charge of assessing new technologies, managing cross-company product portfolios, and leading new projects. He also gained experience as a sales representative for the Ethicon franchise where he was responsible for over 200 Million Yen in revenue for surgical sutures, surgical drains and adhesion barriers across multiple specialties such as general surgery, gynecology, cardiology, and orthopedics.

Bio coming soon.

Bio coming soon.

Dr. Russo is the Founder & Chairman of GEO Semiconductor (www.geosemi.com) since 2014, after having served as Chairman & CEO from its founding in 2008. Dr. Russo also serves as a Director of Achelios Therapeutics (www.achelios.com), Beam Semiconductor (www.beamshaping.io), InBay Technologies (www.inbaytech.com) and several other technology and life science start-ups (Dynamount, Illuminati, Exodos and others). Dr. Russo is heavily involved with the Band of Angels and other similar organizations which review over 1,000 start-ups' business plans per year. He is also a Board Advisor to BWG, LLC. Dr. Russo has served as an outside director of ATI Technologies from 2001 through its acquisition by AMD in 2006.

Prior to founding GEO Semiconductor, Dr. Russo founded Silicon Optix in 2000, a privately held fabless semiconductor company, serving as its Chairman & CEO through 2008. Prior to Silicon Optix, Dr. Russo was the founder, Chairman and CEO of Genesis Microchip (acquired by ST Micro in 2007) following its very successful NASDAQ IPO in 1998.

Prior to founding Genesis, he was General Manager of General Electric Microelectronics Center, Senior Manager of General Electric Industrial Electronics Group and Head, Microsystems Research at RCA's David Sarnoff Research Center. While at RCA, Dr. Russo worked on the world first CMOS microprocessor and pioneered the first use of microprocessors in global communications, programmable video games, TV manufacturing automation and automotive engine control.

Dr. Russo received his B.Eng. from McGill University (Canada) and his M.Sc. and Ph.D. in EECS from UC Berkeley. He holds eight U.S. patents, is a fellow of IEEE and has received numerous RCA and industry awards, including the IEEE Centennial Medal and the 2006 Tech Pioneer Award from the World Economic Forum.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

A highly driven communicator with nearly 20 years’ experience and an exceptional track record in delivering business value for healthcare companies. Skilled in providing strategic counsel to senior-level executives on corporate reputation, developing strong external relationships, and cross-functional working. Deep experience working in highly regulated industries, spanning diverse and complex markets. Passionate about improving access to care for people around the world.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.